Market
Is Life Sciences Law Actually Hiring in 2026?
A supply-and-demand reality check. Life sciences is a regulatory-plus-transactional hybrid — and the specialist bench is small relative to the live mandate flow we see. Demand is heavy and concentrates at partner level, which changes what 'life sciences is hiring' really means for your next move.
One specialism. Two demand engines. A thin bench in the middle.
Pick the force pushing on life-sciences hiring. The number that drives the work moves — and so does the pressure on a scarce senior pool.
Novel drugs the FDA’s CDER approved in 2025 — 34 new molecular entities and 12 biologics, each a years-long stack of regulatory, IP, reimbursement and commercial-counsel work. FDA / CDER ↗
Two engines, regulatory and transactional, drive at once — and the lawyers who can serve both are scarce. Against this flow we map a comparatively thin specialist bench (1,500+ US, banded). Every public figure is cited below.
A thin bench, a heavy demand curve.
"Is life sciences law hiring?" is the wrong question. The right one is at what level, and against how much work. Life sciences is a hybrid practice: it sits where FDA and regulatory law meets the transactional book — licensing, collaborations, financings and M&A — and the lawyers who can do both at once are not plentiful. On the supply side our market mapping shows a comparatively modest specialist bench. On the demand side the mandate flow is heavy and two-sided, and the openings concentrate at partner level. This page sets the two against each other, with banded internal structure on the supply line and live, recomputed demand plus cited public data on the demand line.
Two ground rules, so nothing here overreaches. Our internal figures are a single structural cross-section of the major US & UK firms (May–June 2026) — they describe the shape of the bench, never a trend or a year-over-year move. Every figure about regulatory volume, deal activity or market direction is attributed to a named public source below. Where a figure could not be verified, we left it out rather than approximate it.
“Is life sciences law hiring?” is the wrong question. The right one is at what level, and against how much work.
The bench is thin. The demand is heavy and senior.
Here is the core tension in one table: a banded specialist bench on the supply side, against the live demand our board is actually carrying on the demand side. The bench figures are a banded structural snapshot of our market mapping; the demand figures are recomputed every time this page is built, so they track the market rather than any single survey date.
- The hybrid specialist poolLawyers who pair FDA-regulatory fluency with transactional firepower — already a comparatively thin bench.
- Those who are genuinely seniorThe combination, held at the level where firms compete hardest — thinner still.
- With a portable, clean bookSenior, hybrid, and a relationship that actually travels conflicts-free — the choke point.
- The partner seatWhere most of the live demand sits, and where the bench cannot keep up.
| Measure | Figure | Side | What it tells you |
|---|---|---|---|
| US specialist bench | 1,500+ | Supply | Lawyers we map in the US with life-sciences speciality experience — a comparatively thin pool for a hybrid practice. |
| Global specialist bench | 2,000+ | Supply | The same bench worldwide across the firms we map — modest next to the live mandate flow. |
| Live life-sciences openings | 449 | Demand | Life-sciences legal roles open on our board right now, across firms and markets. |
| Partner-level demand | 403 | Demand | Of the live openings, the partner-level share — about 90% — where the real scarcity sits. |
| Associate & counsel demand | 46 | Demand | The mid-and-junior remainder — a smaller pool, but easier to fill than the partner seats. |
Read the table top-to-bottom: a 1,500+ US bench against 449 live roles, of which 90% are partner-level. That is a demand curve pressing hard on a thin senior pool — the defining feature of a hybrid specialism. Bench figures: our market mapping, structural snapshot; demand figures: our live openings feed (build-time). See the sources below.
A demand curve pressing hard on a thin senior pool — the defining feature of a hybrid specialism.
Why the demand runs from two directions at once.
Life-sciences legal demand is not abstract, and it is not one-dimensional. It is generated by a steady regulatory pipeline and a heavy transactional cycle at the same time. On the regulatory side, the FDA's Center for Drug Evaluation and Research (CDER) approved 46 novel drugs in 2025 — 34 new molecular entities and 12 biologics — each one a stack of regulatory, IP, reimbursement and commercial-counsel work that runs for years before and after approval.
On the transactional side, the deal cycle turned hard. Per EY's M&A Firepower report, life-sciences M&A reached roughly $240 billion in 2025 — an 81% jump on the prior year's ~$130 billion — as developers raced to refill pipelines ahead of a patent cliff that, per Evaluate (cited in the same R&D World report), will see $300 billion+ of branded drug revenue lose exclusivity through 2030. Every one of those acquisitions, licensing deals and collaborations is a fresh transactional mandate layered on top of the regulatory book — which is precisely why firms are rebuilding life-sciences benches and why the hiring skews senior.
The market-wide signal, all public and cited — what is generating the mandates in the first place.
- 46
- Novel drugs the FDA's CDER approved in 2025 — 34 new molecular entities and 12 biologics, each years of regulatory, IP and commercial-counsel work.
- FDA / CDER (2025 novel-drug approvals)
- $240B
- Life-sciences M&A in 2025 — an 81% jump on the prior year's ~$130B, per EY's Firepower report.
- EY M&A Firepower 2025 (via R&D World)
- $300B+
- Branded drug revenue set to lose exclusivity through 2030 — the patent cliff developers are racing to refill ahead of.
- Evaluate (via R&D World)
The demand as it lands on our board right now — recomputed at build time, so it tracks each deploy.
- 449
- Live life-sciences legal openings on our board right now — 403 partner-level and 46 associate/counsel.
- Sartori & Partners openings feed (live, build-time)
- 90%
- Share of live life-sciences demand that is partner-level — the clearest sign the work outpaces the senior bench.
- Sartori & Partners openings feed (live, build-time)
- $225k–$495k
- Advertised pay range across life-sciences roles that disclose a band — senior, hybrid-skill economics sit at the top of it.
- Sartori & Partners openings feed (live, build-time)
Live figures are recomputed every time this page is built, so they track our board rather than any single date. The 46 novel-drug-approval count and the $240 billion 2025 deal figure are public — see the sources. Browse the live board.
Every deal is a fresh transactional mandate layered on top of the regulatory book — which is precisely why the hiring skews senior.
The work concentrates in the biopharma and regulatory hubs.
Life-sciences legal demand is not evenly spread across the map — it clusters where the drug developers, their regulatory counsel and the deal teams that serve them physically sit. Across our live openings, the deepest markets for life-sciences roles are the research, capital and regulatory centres, in this order:
- Research clustersDrug developers and the science — where the regulatory and IP work originates.
- CapitalThe financings and deal teams that fund and trade the pipelines.
- Regulatory gravityFDA-regulatory counsel and the reimbursement machinery around it.
| Metro | Live life-sciences openings |
|---|---|
| New York | 33 |
| Washington | 33 |
| San Francisco | 22 |
| Los Angeles | 22 |
| Boston | 21 |
| Chicago | 21 |
The concentration is the point. Life-sciences mandates flow to lawyers embedded in an FDA-regulatory, IP or transactional ecosystem, so the openings pool around the research clusters and the capital that funds them rather than spreading thin. For a candidate that means technical depth and network matter as much as the practice line; for a hiring firm it means the deepest hybrid talent is found, not advertised. Figures: our live openings feed, recomputed at build time.
What the supply-and-demand picture means for your move.
If you are a life-sciences lawyer
The thin bench works in your favour — if your profile is genuinely hybrid. The lawyers firms compete hardest for are the ones who pair FDA-regulatory fluency with transactional firepower; a single-track regulatory or single-track corporate label is far more replaceable than the combination. At partner level the math is starkest: demand is heavy against a scarce senior pool, and a portable client relationship plus a clean conflicts profile is the asset firms will pay a premium for. Either way, the strongest moves are made quietly, before a role is posted — which is exactly the conversation our candidate process is built for. For the practice context, see our life-sciences practice page.
If you are hiring life-sciences counsel
Read the demand curve before you build. A thin specialist bench means the constraint is real at every level and acute at the top, where you are competing for a small set of hybrid lawyers whose books actually travel. Underwrite a lateral on a portable relationship, demonstrable regulatory and deal experience, and a clean conflicts profile — not on a practice line alone — and time transactional builds to the deal cycle the data above describes. We run these as lateral partner recruiting and associate & attorney recruiting, and we map the whole field first in our methodology. Roles are live on the board now.
FDA / CDER novel-drug approvals, 2025
34 new molecular entities and 12 biologics — the steady regulatory pipeline (a count, anchored to this axis only as a reference point).
FDA / CDER ↗The deepest hybrid talent is found, not advertised.
The evidence behind this read.
We do not invent statistics. Internal figures are a banded structural snapshot of our market mapping; every regulatory, demand and deal figure is attributed to a named public source.
The evidence behind this read
4 referencesInternal figures describe the shape of the market at a point in time, not its direction; the specialist bench is banded (1,500+ US, 2,000+ globally) and no firm names are attached. Public figures are current as of the FDA's 2025 novel-drug-approvals record and EY's 2025 M&A Firepower report (accessed June 2026) and refer to 2025 activity. The live opening, split, partner-share, pay-band and metro figures are computed from our openings feed (vacancies.json) at build time and track each deploy. Demand and pay vary by market, firm, level and hours.
Keep reading.
Life sciences legal hiring: FAQ
The questions life-sciences lawyers and hiring partners ask most — answered, with the same content behind our FAQ structured data.
Is life sciences law actually hiring in 2026?
Yes — heavily, and at the senior end. As of this build there are 449 live life-sciences legal openings on our board, and 403 of them (about 90%) are partner-level roles versus 46 associate and counsel roles. The demand is driven from two directions at once: a steady stream of regulatory work (the FDA's CDER approved 46 novel drugs in 2025) and a transactional wave (life-sciences M&A reached roughly $240 billion in 2025, an 81% jump on the prior year, per EY's Firepower report). Against that mandate flow, the specialist bench is comparatively thin — which is exactly why so much of the hiring is at partner level.
Is there a shortage of life sciences lawyers?
Relative to the work, yes — especially senior. Life sciences is a hybrid specialism: it asks for regulatory fluency (FDA, biologics, reimbursement) and transactional firepower (licensing, collaborations, M&A) in the same lawyer, and that combination is genuinely scarce. In our market mapping we count 1,500+ US lawyers and 2,000+ globally with life-sciences speciality experience (proprietary mapping of the major US & UK firms, 275,000+ practising lawyers, May–June 2026) — a modest bench next to the 449 live openings our board is carrying. The constraint bites hardest at partner level, where about 90% of live demand sits.
Where are life sciences legal jobs concentrated in 2026?
In the biopharma and regulatory hubs. Across our live openings, life-sciences demand clusters in New York (33), Washington (33), San Francisco (22), Los Angeles (22) — the cities where the drug developers, their regulatory counsel and the deal teams that serve them physically sit. The work is technical and locally networked: life-sciences mandates flow to lawyers embedded in an FDA-regulatory, IP or transactional ecosystem, which is why the openings concentrate around the research, capital and regulatory centres rather than spreading evenly across the map.
Start a conversation
Hiring life-sciences counsel, or weighing a move?
The bench is thin, the demand runs from two directions, and the best moves happen quietly. We map the field first, then make the calls that matter. No name circulated, no obligation.